Liver preservation solution

Abstract

The invention discloses a liver preservation solution which contains the following components in per 100ml: 7-8g of 1,6-fructose diphosptate, 1-2g of glutathione, 2-3g of allopurinol, 0.3-0.5g of traditional Chinese medicine ligustrazine, 8-12mg of traditional Chinese medicine anisodamine and the balance of Ringer's solution added to 100ml. Proved by a large number of experiments, the liver preservation solution has a statistical meaning compared with an experiment contrast group, and two treatment groups (a group of the invention and an American UW treatment group) do not have the statistical meaning. The invention provides an excellent guarantee for long-acting liver preservation, has simple prescription and saves production and inspection cost for production and clinical application.

Description

technical field [0001] The invention relates to an organ preservation solution, in particular to a liver preservation solution, and belongs to the technical field of biomedicine. Background technique [0002] With the widespread development of liver transplantation, the contradiction between the shortage of donor sources and the surge in the number of patients waiting for liver transplantation has become increasingly apparent. The lack of donors requires a reasonable allocation of transplanted organs. In order to make full use of the organs of each donor, long-distance transportation is often required. In this way, the cold storage time of transplanted organs is gradually prolonged, and the cold storage reperfusion injury is becoming more and more serious. Although organ preservation technology has been well developed, according to the statistics of foreign authoritative organizations, 4% of donated livers and kidneys are still discarded due to various factors, and early non...

AI Technical Summary

Problems solved by technology

However, at present, the prescription of this kind of preservation solution is complicated, which brings a very tedious workload to the production and quality control of the preservation solution.

Moreover, the finished product is not conducive to end consumers, because the cumbersome configuration process and quality control consume a lot of resources, and at the same time, it will inevitably bring high costs and increase the burden on patients

[0019] Domestically, a lot of research work has been done on the protection of ischemia-reperfusion injury in liver transplantation. From the perspective of organ preservation in my country, we still lack long-term organ preservation that can preserve multiple organs, such as UW and HTK, which have been widely used in the world. This will be a factor limiting the further development of organ transplantation in my country

Images